Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ClinicalTrials.gov Oversteps Corporate Confidentiality Protections – Merck

Apr 22 2002

• By The Pink Sheet

Related Content

Phase IV Protocol Submissions Should Not Have Time Limits, Merck Tells FDA

Aug 06 2001

FDA Sets 45-Day Deadline For Listing Studies In ClinicalTrials.Gov

Mar 25 2002

Merck Vaccine Shipments Resume; CDC Varivax Orders On 8-Week Backlog

Feb 11 2002

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window